MEDIA RELEASE PR41919
Eighth CyberKnife System in South Korea Installed and Treating Patients
SUNNYVALE, Calif., Oct. 27 /PRNewswire-AsiaNet/ --
Installation at Korea Cancer Care Hospital Marks First Hospital
in Asia with Two CyberKnife Systems in Use
Accuray Incorporated (Nasdaq: ARAY), a global leader in the field of
radiosurgery, today announced that the Korea Cancer Care Hospital (KCCH) in
Seoul, South Korea has installed its second CyberKnife(R) Robotic
Radiosurgery System, marking the first hospital in the country - and Asia -
to have two CyberKnife Systems in use.
The recently acquired CyberKnife System is located at the Asia Cancer
Center (ACC), the new cancer hospital of KCCH located in Busan. It represents
the eighth CyberKnife System in South Korea and the country's first equipped
with a linear accelerator capable of delivering a dose rate of 1,000MU
(monitor unit) per minute, which improves the system's efficiency.
"We are very pleased to be the first hospital in South Korea with two
CyberKnife Systems in use," said Dr. Kwang Mo Yang, Chief of Cancer Research
Division and Radiation Oncologist at ACC. "The CyberKnife System, a
state-of-the-art form of cancer care will enable us to expand our radiation
offerings to patients who may not have been able to tolerate other treatments
or have medically or surgically inoperable tumors. With this additional
capability at ACC, the CyberKnife System is a definite asset for our
treatment program, offering an alternative to our patients and establishing
the ACC's role as 'The First Medical Hub of Asia.'"
"We are very proud that the CyberKnife System has been serving Korean
patients and KCCH, one of the most prestigious cancer care and research
institutes, for eight years," said Cynthia Chan, Director of Marketing,
Accuray APAC. "CyberKnife technology is increasingly accepted by the medical
community in Korea. The second CyberKnife System with the newest product
enhancements now being used at ACC not only broadens patient access, but also
contributes to the clinical development of radiosurgery and high precision
radiotherapy in Korea."
Korea Cancer Care Hospital has been one of the nation's leading cancer
centers for over four decades. In 2002, KCCH installed their first CyberKnife
System and established their medical complex composed of a hospital, research
center, and the national radiation emergency medical center. Today, the
second CyberKnife System installed treating patients at ACC, the KCCH's Busan
branch, will help to play an important role in enhancing medical welfare,
improving research of radiation medicine, and providing world class
treatment.
About Asia Cancer Center
ACC is a 300 bed facility offering a specialized cancer prevention
center, research center and radiation emergency medical center. ACC intends
to offer facilities such as a sea park, resort and golf course with the
vision to establish "The First Medical Hub of Asia" offering tourism,
recuperation and treatment all in one place. ACC will establish ten cancer
sub-centers specializing in stomach, lung, liver, colorectal, breast,
cervical and thyroid cancers, as well as clinical service center and cancer
prevention center. A series of sensitivity treatments such as psychology,
languages, fine arts and ceramic arts will also be provided to assist in the
complete rapid recovery of patients.
About the CyberKnife(R) Robotic Radiosurgery System
The CyberKnife Robotic Radiosurgery System is the world's only robotic
radiosurgery system designed to treat tumors anywhere in the body
non-invasively. Using continual image guidance technology and computer
controlled robotic mobility, the CyberKnife System automatically tracks,
detects and corrects for tumor and patient movement in real-time throughout
the treatment. This enables the CyberKnife System to deliver high-dose
radiation with pinpoint precision, which minimizes damage to surrounding
healthy tissue and eliminates the need for invasive head or body
stabilization frames.
About Accuray
Accuray Incorporated (Nasdaq: ARAY), based in Sunnyvale, Calif., is a
global leader in the field of radiosurgery dedicated to providing an improved
quality of life and a non-surgical treatment option for those diagnosed with
cancer. Accuray develops and markets the CyberKnife Robotic Radiosurgery
System, which extends the benefits of radiosurgery to include extracranial
tumors, including those in the spine, lung, prostate, liver and pancreas. To
date, the CyberKnife System has been used to deliver more than 100,000
treatments worldwide and currently more than 206 systems have been installed
in leading hospitals in the Americas, Europe and Asia. For more information,
Safe Harbor Statement
The foregoing may contain certain forward-looking statements that involve
risks and uncertainties, including uncertainties associated with the medical
device industry. Except for the historical information contained herein, the
matters set forth in this press release, including statements relating to
multiple units, patient treatment volumes, clinical acceptance, clinical
benefits and investments in radiosurgery are forward-looking statements
within the meaning of the "safe harbor" provisions of the Private Securities
Litigation Reform Act of 1995. Forward-looking statements speak only as of
the date the statements are made and are based on information available at
the time those statements are made and/or management's good faith belief as
of that time with respect to future events. You should not put undue reliance
on any forward-looking statements. Important factors that could cause actual
performance and results to differ materially from the forward-looking
statements we make include: market acceptance of products; competing
products, the combination of our products with complementary technology; and
other risks detailed from time to time under the heading "Risk Factors" in
our report on Form 10-K for the 2010 fiscal year which has been filed with
the Securities and Exchange Commission filed on August 31, 2010. The
Company's actual results of operations may differ significantly from those
contemplated by such forward-looking statements as a result of these and
other factors. We assume no obligation to update forward-looking statements
to reflect actual performance or results, changes in assumptions or changes
in other factors affecting forward-looking information, except to the extent
required by applicable securities laws.
SOURCE: Accuray Incorporated
CONTACT: Stephanie Tomei, Senior Manager, Marketing Communications of
Accuray Incorporated,
+1-408-789-4234,
stomei@accuray.com, or
Kaman Ng, Marcom Manager, Accuray Asia,
+852 2247-8622,
kng@accuray.com
NEWS 
